Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the US
Zydus Lifesciences’ (formerly known as Cadila Healthcare) subsidiary Zydus Pharmaceuticals (USA). (Zydus) has launched Topiramate extended-release capsules. The company had earlier received final approval from the United States Food and Drug Administration (US FDA) to market Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg (USRLD: Trokendi XR). Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the US.
Topiramate Extended-Release capsule is indicated for Epilepsy: initial monotherapy in patients 6 years of age and older with partial-onset or primary generalised tonic-clonic seizures; adjunctive therapy in patients six years of age and older with partial-onset, primary generalised tonic-clonic seizures, or seizures associated with Lenox-Gastaut Syndrome (LGS). It is also indicated for prophylaxis of migraine in patients 12 years of age and older.
